1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant
    Meeting Abstract

    Foley, N. C.; Russler-Germain, D.; Watkins, M.; Jacobsen, E. D.; Moskowitz, A. J.; Cashen, A. F.; Fehniger, T. A.; Kahl, B. S.; Ghobadi, A.; Reagan, B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy
    Meeting Abstract

    Nastoupil, L. J.; Kamdar, M. K.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López Guillermo, A.; Martinez-Lopez, J.; Novak, U.; Ribrag, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study
    Meeting Abstract

    Falchi, L.; Carlo-Stella, C.; Morschhauser, F.; Hutchings, M.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma
    Meeting Abstract

    Samples, L. S.; Sadrzadeh, H.; Frigault, M. J.; Jacobson, C. A.; Hamadani, M.; Gurumurthi, A.; Strati, P.; Shouval, R.; Riedell, P. A.; Dahiya, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting
    Meeting Abstract

    Moslehi, J. J.; Aras, M. A.; Oehler, V. G.; Thompson, J. E.; McCloskey, J. K.; Heinrich, M. C.; DeGutis, I. S.; Fish, S. M.; Mauro, M. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Epcoritamab + R (2) regimen and responses in high-risk follicular lymphoma, regardless of POD24 status
    Meeting Abstract

    Merryman, R.; Belada, D.; Sureda, A.; Leppä, S.; Vermaat, J. S. P.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study
    Meeting Abstract

    Herrera, A. F.; Tracy, S.; Sehn, L. H.; Jardin, F.; Lenz, G.; Trneny, M.; Salles, G. A.; Flowers, C.; Tilly, H.; Sharman, J. P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment
    Meeting Abstract

    Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I. W.; Alencar, A. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data
    Meeting Abstract

    Falchi, L.; Clausen, M.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study
    Meeting Abstract

    Passamonti, F.; Patriarca, A.; Knapper, S.; Rivera, C.; Scandura, J.; Devos, T.; Granacher, N.; Mead, A. J.; Oh, S.; Palmer, J. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save